Allergan exercises option for Editas' EDIT-101

Allergan plc (NYSE:AGN) exercised its option under a 2017 deal and will receive worldwide rights to develop and commercialize in vivo CRISPR-based therapy EDIT-101 from Editas Medicine Inc. (NASDAQ:EDIT) to treat Leber congenital amaurosis type 10 (LCA10). The two companies also announced that Editas exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the U.S.

Editas received a $15 million option exercise fee and is eligible for an additional $25 million from Allergan upon acceptance of an IND for EDIT-101 by FDA (see "Editas, Allergan Deal")...